1. Home
  2. PLSM vs MRKR Comparison

PLSM vs MRKR Comparison

Compare PLSM & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PLSM

Pulsenmore Ltd. Ordinary Shares

N/A

Current Price

$4.39

Market Cap

22.0M

Sector

Health Care

ML Signal

N/A

Logo Marker Therapeutics Inc.

MRKR

Marker Therapeutics Inc.

HOLD

Current Price

$1.45

Market Cap

24.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLSM
MRKR
Founded
2014
1999
Country
Israel
United States
Employees
63
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.0M
24.2M
IPO Year
N/A
2010

Fundamental Metrics

Financial Performance
Metric
PLSM
MRKR
Price
$4.39
$1.45
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
34.4K
56.3K
Earning Date
03-30-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
33.61
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$936.27
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.00
$0.81
52 Week High
$7.15
$4.07

Technical Indicators

Market Signals
Indicator
PLSM
MRKR
Relative Strength Index (RSI) 50.15 45.96
Support Level $3.73 $1.35
Resistance Level $5.00 $1.52
Average True Range (ATR) 0.37 0.06
MACD -0.03 0.00
Stochastic Oscillator 29.84 22.73

Price Performance

Historical Comparison
PLSM
MRKR

About PLSM Pulsenmore Ltd. Ordinary Shares

Pulsenmore Ltd is an emerging medical device company engaged in the research, development, manufacturing, marketing, and sale of non-invasive portable ultrasound solutions for home use. Its products include the Pulsenmore ES and Pulsenmore FC, along with the early-stage Pulsenmore MC, collectively referred to as Pulsenmore Products, enabling remote ultrasound scans in gynecology and other fields such as pulmonary, cardiology, and urology through telemedicine. The Company operates in a single segment focused on developing and commercializing portable ultrasound technologies, with Israel contributing the majority of its revenue.

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).

Share on Social Networks: